Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from in vitro healthy cells and malignant pleural mesothelioma cell lines infected by oncolytic attenuated measles virus or treated by exogenous type I interferon

ABSTRACT: Expression data from in vitro healthy cells and malignant pleural mesothelioma cell lines infected by oncolytic attenuated measles virus or treated by exogenous type I interferon

PROVIDER: PRJNA482853 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data from in vitro healthy cells and malignant pleural mesothelioma cell lines infected by oncolytic attenuated measles virus or treated by exogenous type I interferon

Project description:We used microarrays to analyse antiviral response by mesothelioma cells sensitive or resistant to the oncolytic activity of measles virus

2018-07-26 | GSE117668 | GEO

Copy number variations analysis by CytoscanHD array of 33 human pleural mesothelioma cell lines

Project description:We performed a cytoscanHD array to analyze copy number variations in the genome of 33 human pleural mesothelioma cell lines established from patient pleural effusion. We were particularly interested in the analysis of the p21.3 region of chromosome 9 which contains CDKN2A tumor suppressor genes and the gene encoding type I interferons that are often deleted and confer sensitivity to oncolytic Measles virus

2019-07-17 | GSE134349 | GEO

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

Project description:Regional delivery of oncolytic viruses has been shown to promote immune responses. Malignant pleural effusions comprise an immunosuppressive microenvironment, and the ability of oncolytic viruses to generate immune responses following regional delivery in patients with malignant pleural effusions is unknown. We conducted a phase I clinical trial that studied the intrapleural administration of oncolytic vaccinia virus to establish the safety and feasibility in patients with malignant pleural effusion due to malignant pleural mesothelioma or metastatic disease. In patients with malignant pleural mesothelioma, by correlative analysis of pre- and post-treatment tumor biopsies, we provide insight into tumor-specific viral uptake and associated immune responses.

2023-01-27 | GSE223395 | GEO

Bulk RNA-seq profiling of pleural mesothelioma and comparator pleural specimens

Project description:This GEO submission contains processed bulk RNA sequencing data generated from pleural mesothelioma tumors and comparator pleural specimens. Raw sequencing data are available through controlled access in dbGaP under accession phs004285. Processed gene expression matrices and sample-level metadata for the bulk RNA-seq libraries are provided in this submission.

2026-04-07 | GSE327166 | GEO

Identification of novel markers for malignant pleural mesothelioma diagnosis

Project description:Diagnosis of malignant pleural mesothelioma (MPM) is difficult, the most common differential diagnosis being benign pleural diseases and metastatic adenocarcinomas. In order to identify novel markers able to improve diagnostic accuracy, we performed a genome-wide gene expression analysis on tumor cells lines established from pleural effusions (13 MPM and 4 lung adenocarcinoma). Our microarray analysis led to the identification of genes encoding novel cellular and soluble markers whose expression was validated by RT-qPCR. Immunohistochemical staining of tumor biopsies with anti-type-III collagen antibodies were positive in mesothelioma cells but not in adenocarcinoma cells. Using ELISA, we showed that the C-C motif chemokine 2 (CCL2) concentration was significantly higher in pleural effusions from patients with mesothelioma (n = 61) than in subjects with adenocarcinoma (n = 25) or with benign pleural effusions (n = 15): median (interquartile range) = 2.99 ng/mL (1.76-6.01) versus 0.99 ng/mL (0.51-1.83) and 1.47 ng/mL (0.80-1.56), respectively, P < 0.0001. Conversely, the galectin-3 concentration was lower in mesothelioma: 11.50 ng/mL (6.73-23.53) versus 24.74 ng/mL (20.42-70.35) and 17.64 ng/mL (14.81-24.68), respectively, P < 0.0001. The AUC for CCL2 were 0.8030 and 0.7716 for differentiating mesothelioma from adenocarcinoma or benign effusions, respectively. Similarly, the AUC obtained for galectin-3 were 0.7980 and 0.6923, respectively. In conclusion, type-III collagen, CCL2 and galectin-3 are promising new diagnostic markers for mesothelioma.

2009-07-25 | GSE17310 | GEO

Single-cell RNA-seq profiling of pleural mesothelioma and comparator pleural specimens

Project description:This GEO submission contains processed single-cell RNA sequencing data generated using the Seq-Well platform from pleural mesothelioma tumors and comparator pleural specimens. Raw sequencing data are available through controlled access in dbGaP under accession phs004285. Processed expression matrices and cell-level metadata for the single-cell libraries are provided in this submission.

2026-04-07 | GSE327167 | GEO

Targeted spatial transcriptomic profiling of pleural mesothelioma using 10x Genomics Xenium

Project description:Targeted spatial transcriptomic profiling was performed on seven formalin-fixed paraffin-embedded pleural mesothelioma tumor samples from four cases using the 10x Genomics Xenium platform. The Xenium Human Immuno-Oncology panel supplemented with 100 additional custom genes selected from known pleural mesothelioma biomarkers and single-cell RNA-seq-derived marker genes was used. Raw and processed Xenium files are provided for each sample. To ensure data integrity with downloaded Xenium files, md5 checksums are provided in 'Xenium_GEO.md5'. This dataset is part of a multi-modality study including matched scRNA-seq, bulk RNA-seq, and Xenium spatial transcriptomics generated from overlapping pleural mesothelioma samples. Related controlled-access sequencing data are available in dbGaP under accession phs004285.

2026-04-08 | GSE327347 | GEO

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Project description:RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person’s pleural cavity may improve the body’s ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignant pleural effusions.

| 2009653 | ecrin-mdr-crc

CDKN2A deletion remodels immune infiltrate in Diffuse Pleural Mesothelioma

Project description:RNA extracted from diagnostic tumor samples of 82 patients affected by Diffuse Pleural Mesothelioma was analyzed on the nCounter system using the PanCancer Immune Profiling Panel.

2025-09-03 | GSE302048 | GEO

Transcription profiling of human pleural mesothelioma versus parietal and visceral pleura

Project description:Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura

2009-01-01 | E-MTAB-47 | biostudies-arrayexpress